NCT05632926View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1)

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 9, 2023

Primary Completion Date

May 3, 2023

Study Completion Date

May 3, 2023

Conditions
Cellulite
Interventions
DRUG

40 mg CBL-514

CBL-514 will be administered at the raised area of cellulite.

DRUG

60 mg CBL-514

CBL-514 will be administered at the raised area of cellulite.

DRUG

80 mg CBL-514

CBL-514 will be administered at the raised area of cellulite.

Trial Locations (2)

10022

Investigational Site 2, New York

91436

Investigational Site 1, Encino

Sponsors
All Listed Sponsors
lead

Caliway Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT05632926 - A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1) | Biotech Hunter | Biotech Hunter